Initially, after market-close on June 27, 2016, Regulus announced that the U.S. Food and Drug Administration ("FDA") had put RG-101 on clinical hold after a second serious case of jaundice was reported during clinical trial. After the announcement, Regulus's share price fell from $5.01 per share on June 27, 2016 to a closing price of $2.54 on June 28, 2016 —a $2.38 or a 49.3% drop.
Then, after market-close on January 27, 2017, Regulus revealed that the FDA would not reconsider the clinical hold on RG-101 until the agency had received the final safety and efficacy data from ongoing clinical and pre-clinical studies. The Company expects that the requested data will be available in the fourth quarter of 2017. After the announcement, Regulus's share price dropped from $ 2.25 per share on January 27, 2017 to a price of $1.05 on January 30, 2017 or a 53.3% decrease.
Request more information now by clicking here: www.faruqilaw.com/RGLS. There is no cost or obligation to you.
If you invested in Regulus stock or options and would like to discuss your legal rights, visit www.faruqilaw.com/RGLS. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Regulus's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Telephone: (877) 247-4292 or (212) 983-9330
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/regulus-notification-faruqi--faruqi-llp-encourages-investors-who-suffered-losses-in-excess-of-100000-investing-in-regulus-therapeutics-inc-to-contact-the-firm-300399007.html
SOURCE Faruqi & Faruqi, LLP